CClinicalTrials.gg
CompletedNCT02668029Updated Jan 29, 2016

Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis

A Phase 2 interventional study of oxygen and medical air in Pulmonary Fibrosis, sponsored by University of Siena. Completed. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2016-01-29.

Sponsored by University of Siena · Phase 2, Interventional, and Supportive care

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Patients with pulmonary fibrosis often desaturate on exercise. There are no data showing whether ambulatory oxygen can be useful to improve exercise capacity in this condition. Ambulatory ambulatory oxygen is often denied to these patients based on studies conducted on patients with chronic obstructive pulmonary disease, a completely different condition for physiopathology, prognosis, and response to therapy. We therefore planned a controlled study to verify the usefulness of ambulatory oxygen in patients with pulmonary fibrosis

Read the detailed description

Criteria for inclusion: Patients with a diagnosis of pulmonary fibrosis of any kind, with oxygen saturation >90% in ambient air at rest, showing a desaturation \<88% during a preliminary 6 minutes walking test Criteria for exclusion: Inability to give consent, age \<18 or >85 years, walking problems from causes different from pulmonary disease

Procedure:

In a preliminary session, the flow of oxygen needed to prevent desaturation during walking is established according to a validated protocol Guyatt et al, Am J Respir Crit Care Med 2001,163:,942-946.) Two 6 minutes walking tests are then performed in a corridor, at least 30' apart, during administration of oxygen or medical air, in random order and double blind, at the same pre-determined flow, administered through a nasal cannula connected to a wall outlet (concealed from sight, being in a side rum at about mid distance in the corridor) through a 10 mt plastic tubing. Oxygen saturation and pulse rate are monitored through a dedicated recording oximeter (Minoxy, Cosmed) , whose display is concealed to both the patient and the operator, with an alarm set for oxygen saturation \<70%, to stop the test in case severe desaturation would occur Data are then transferred to computer for analysis only after both test are performed. Walked distance is recorded by the operator unaware of treatment.

At the end of each test, a short questionnaire is administered with 10 cm Visual Analogue Scales (VAS) for dyspnoea, fatigue, and preference compared to performing the test without any treatment. At the end of the second test a further scale is submitted, asking about the preference between the two treatments.

Primary outcomes are the distance walked and the difference in preference of the two treatments compared o no treatment. Secondary outcomes are differences in minimal saturation level and maximal pulse rate during the test and in the report of dyspnea and fatigue at the end of the test, and the reported preference between the two treatments.

Statistical analysis to evaluate the effect of the treatment on walking distance, heart frequency and oxygen saturation is performed using generalized linear model with a gaussian family and identity link and including order of treatment as a fixed effect. Parameters evaluated using VAS are analyzed using Koch adaptation of Wilkoxon rank test (Senn SS. Cross-over Trials in Clinical Research, 2nd Edition. Wiley 2002)

02

Conditions studied

  • Pulmonary Fibrosis

Keywords

  • Oxygen therapy
03

In context

Pulmonary Fibrosis

680 studies on the registry are indexed under Pulmonary Fibrosis; 119 are open to participants now.

This study's enrollment of 32 is below the median of 50 across 419 interventional studies indexed under Pulmonary Fibrosis.

Browse Pulmonary Fibrosis studies →

Lead sponsor

University of Siena is the lead sponsor of 65 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Pulmonary fibrosis of any cause
  • Oxygen saturation => 90% at rest in ambient air, and \<88% during walking test

Exclusion criteria

Exclusion Criteria:

  • Inability to give consent
  • Walking impaired by any condition except pulmonary disease
05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    oxygen

    oxygen administered through a nasal cannula at a personalized, fixed flow

    Drug: oxygen

  • Placebo comparator
    medical air

    Medical air administered through a nasal cannula at the same flow

    Drug: medical air

Interventions

  • Drugoxygen

    information already included in arm/group descriptions.

    Also known as: ambulatory oxygen

  • Drugmedical air

    Placebo

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. distance walked

    recorded by operator

    Time frame: end of test (6 minutes)

  2. Difference in preference of the two treatments compared to no treatment.

    VAS scale

    Time frame: end of test (6 minutes)

Secondary outcomes

  1. Difference in oxygen saturation level

    Digitally recorded

    Time frame: Walking test (6 min)

  2. Difference in heart rate

    Digitally recorded

    Time frame: Walking test (6 min)

  3. Difference in dyspnea at the end of test

    VAS

    Time frame: End of test (6 min)

  4. Difference in fatigue at the end of test

    VAS

    Time frame: End of test (6 min)

  5. Preference between the two treatments

    VAS

    Time frame: End of both tests (45 min)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Guyatt GH, Nonoyama M, Lacchetti C, Goeree R, McKim D, Heels-Ansdell D, Goldstein R. A randomized trial of strategies for assessing eligibility for long-term domiciliary oxygen therapy. Am J Respir Crit Care Med. 2005 Sep 1;172(5):573-80. doi: 10.1164/rccm.200412-1692OC. Epub 2005 May 18. PubMed 15901604 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02668029
Lead sponsor
University of Siena
Responsible party
Piersante Sestini (associate professor, University of Siena) — Principal investigator
First posted
Jan 29, 2016
Start date
Apr 2012
Primary completion
Apr 2013
Completion
Apr 2013
Last update
Jan 29, 2016

Study contacts

Piersante Sestini, MD
principal investigator · University of Siena

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion